Efficacy of oxiracetam combined with nimodipine in the treatment of cognitive impairment patients with type 2 diabetes
10.13699/j.cnki.1001-6821.2015.14.005
- VernacularTitle:奥拉西坦联合尼莫地平对2型糖尿病认知功能障碍患者的临床研究
- Author:
Wei-Wei SHEN
1
;
Xiao-Yun FAN
;
Min LONG
;
Zong-Yi XIE
Author Information
1. 重庆市第六人民医院 内分泌科
- Keywords:
diabetes;
cognitive impairment;
oxiracetam;
nimodipine
- From:
The Chinese Journal of Clinical Pharmacology
2015;(14):1376-1378
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of oxiracetam combined with nimodipine on cognitive impairment patients with type 2 diabetes and to investigate its mechanisms.Methods Ninety patients with cognitive impairment in type 2 diabetes were randomly divided into oxiracetam group (A) (n =30) with oxiracetam 800 mg, tid, po;nimodipine group (B) (n=30) with nimodipine 20 mg, tid, po;and combined group (C) (n=30) with oxiracetam plus nimodipine of the same dose.After tweleve-week treatment,the Montreal cognitive assessment ( MoCA ) and activities of daily living ( ADL ) scale were evaluated.Neuron -specific enolase ( NSE ) and S -100βprotein expressions in blood serum and drug adverse reactions were also evalua-ted.Results After tweleve-week treatment, MoCA score was signifi-cantly increased ( P<0.05 ) and ADL scale was significantly reduced in all of the three groups ( P <0.05 ) , and the changes in the C group was much more obvious than other two groups (P <0.01).After treatment, NSE and S-100βprotein expressions in blood serum of group A and B were obviously reduced compared with before treatment ( P <0.05 ) , while group C were more dramatically reduced compared with A and B group ( P <0.01 ) . No obvious side effect was observed in the period of treatment in all the three groups. Conclusion Oxiracetam combined with nimodipine treatment was superior to either of the single regiment in the treatment of cognitive impairment in type 2 diabetes without increasing the risk of developing side effect by inhibiting NSE and S-100βexpressions.
